ALNY Financial Facts
Total other income (expense): 2.32MNet revenues from research collaborators: 8.71M
See Full Income Statement
Total stockholders' equity: 1.1B
Commitments and contingencies (Notes 4, 5 and 6): 0
See Full Balance Sheet
Alnylam Pharmaceuticals, Inc. (ALNY) Earnings
|
Expand Research on ALNY
| Next EPS Date | 10/29/26 | EPS Growth Rate | -39.0% |
|---|---|---|---|
| Average EPS % Beat Rate | +149.1% | Revenue Growth Rate | +15.3% |
| Average % Move 1-Wk after EPS | -6.5% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
10/29/26  |
Q326 | N/A | $1.77 | N/A | N/A | $1.44B | = | N/A | N/A | ||
| 7/30/26 | Q226 | $1.84 | $1.60 | +$0.24 | $1.29B | $1.32B | = |  | | Details | |
| 4/30/26 | Q126 | $1.99 | $0.91 | +$1.08 | $1.17B | $1.12B | = | | | Details | |
| 2/12/26 | Q425 | $1.25 | $1.19 | +$0.06 | $1.1B | $1.15B | = | | | Details | |
| 10/30/25 | Q325 | $2.90 | $0.52 | +$2.38 | $1.25B | $946.73M | = | | | Details | |
| 7/31/25 | Q225 | $0.32 | -$0.59 | +$0.91 | $773.69M | $643.2M | = | | | Details | |
| 5/1/25 | Q125 | -$0.01 | -$0.93 | +$0.92 | $594.19M | $588.75M | = | | | Details | |
| 2/13/25 | Q424 | $0.06 | -$0.58 | +$0.64 | $593.16M | $580.61M | = | | | Details |
